Wall Street analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to announce ($0.32) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for ADMA Biologics’ earnings, with the highest EPS estimate coming in at ($0.31) and the lowest estimate coming in at ($0.35). ADMA Biologics reported earnings per share of ($0.55) during the same quarter last year, which would suggest a positive year-over-year growth rate of 41.8%. The company is expected to announce its next quarterly earnings report on Friday, August 10th.
According to Zacks, analysts expect that ADMA Biologics will report full-year earnings of ($1.31) per share for the current fiscal year, with EPS estimates ranging from ($1.42) to ($1.21). For the next financial year, analysts forecast that the business will post earnings of ($0.51) per share, with EPS estimates ranging from ($1.00) to $0.00. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow ADMA Biologics.
ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Monday, May 14th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.08). ADMA Biologics had a negative return on equity of 88.31% and a negative net margin of 101.93%. The business had revenue of $4.04 million for the quarter, compared to analyst estimates of $7.47 million.
In related news, Director Jerrold B. Grossman acquired 20,921 shares of the stock in a transaction dated Friday, June 8th. The stock was bought at an average price of $4.78 per share, for a total transaction of $100,002.38. Following the purchase, the director now directly owns 98,007 shares of the company’s stock, valued at approximately $468,473.46. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Adam S. Grossman acquired 52,301 shares of the stock in a transaction dated Friday, June 8th. The stock was bought at an average price of $4.78 per share, with a total value of $249,998.78. Following the purchase, the chief executive officer now directly owns 32,527 shares in the company, valued at $155,479.06. The disclosure for this purchase can be found here. Insiders bought a total of 78,222 shares of company stock valued at $373,901 in the last quarter. 16.90% of the stock is currently owned by company insiders.
Several large investors have recently added to or reduced their stakes in the company. Millennium Management LLC increased its stake in shares of ADMA Biologics by 305.2% in the 1st quarter. Millennium Management LLC now owns 273,621 shares of the biotechnology company’s stock valued at $1,259,000 after acquiring an additional 206,088 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of ADMA Biologics by 420.3% in the 4th quarter. Geode Capital Management LLC now owns 112,000 shares of the biotechnology company’s stock valued at $359,000 after acquiring an additional 90,474 shares in the last quarter. BlackRock Inc. grew its position in ADMA Biologics by 59.5% in the 1st quarter. BlackRock Inc. now owns 40,536 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 15,115 shares during the period. JPMorgan Chase & Co. acquired a new stake in ADMA Biologics in the 1st quarter valued at $182,000. Finally, Element Capital Management LLC acquired a new stake in ADMA Biologics in the 1st quarter valued at $118,000. Institutional investors own 37.50% of the company’s stock.
ADMA Biologics stock traded up $0.08 during mid-day trading on Wednesday, hitting $6.31. 2,439 shares of the stock were exchanged, compared to its average volume of 381,200. The company has a debt-to-equity ratio of 1.76, a quick ratio of 3.60 and a current ratio of 4.92. ADMA Biologics has a 12 month low of $2.01 and a 12 month high of $6.86. The firm has a market cap of $282.32 million, a price-to-earnings ratio of -3.30 and a beta of 2.40.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.